[go: up one dir, main page]

WO1994017792A3 - Compositions and methods for transdermal drug delivery - Google Patents

Compositions and methods for transdermal drug delivery Download PDF

Info

Publication number
WO1994017792A3
WO1994017792A3 PCT/US1994/000896 US9400896W WO9417792A3 WO 1994017792 A3 WO1994017792 A3 WO 1994017792A3 US 9400896 W US9400896 W US 9400896W WO 9417792 A3 WO9417792 A3 WO 9417792A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
drug delivery
transdermal drug
iontophoresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/000896
Other languages
French (fr)
Other versions
WO1994017792A2 (en
Inventor
Harold E Selick
Kevin R Oldenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Affymax Technologies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies NV filed Critical Affymax Technologies NV
Priority to JP6518085A priority Critical patent/JPH08510720A/en
Priority to AU67647/94A priority patent/AU6764794A/en
Priority to EP94915749A priority patent/EP0683668A4/en
Publication of WO1994017792A2 publication Critical patent/WO1994017792A2/en
Publication of WO1994017792A3 publication Critical patent/WO1994017792A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of delivering nucleotide-based pharmaceutical agents across membranes, such as the dermis or skin layer of a patient using iontophoresis.
PCT/US1994/000896 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery Ceased WO1994017792A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP6518085A JPH08510720A (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery
AU67647/94A AU6764794A (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery
EP94915749A EP0683668A4 (en) 1993-01-27 1994-01-26 COMPOSITIONS AND METHODS FOR TRANSDERMAL ADMINISTRATION OF MEDICINES.

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US946393A 1993-01-27 1993-01-27
US08/009,463 1993-01-27
US7778693A 1993-06-14 1993-06-14
US7729693A 1993-06-14 1993-06-14
US08/077,786 1993-06-14
US08/077,296 1993-06-14
US10732993A 1993-08-16 1993-08-16
US08/107,329 1993-08-16

Publications (2)

Publication Number Publication Date
WO1994017792A2 WO1994017792A2 (en) 1994-08-18
WO1994017792A3 true WO1994017792A3 (en) 1994-09-29

Family

ID=27485882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000896 Ceased WO1994017792A2 (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery

Country Status (5)

Country Link
EP (1) EP0683668A4 (en)
JP (1) JPH08510720A (en)
AU (1) AU6764794A (en)
CA (1) CA2153243A1 (en)
WO (1) WO1994017792A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846635B1 (en) 1999-07-30 2005-01-25 Large Scale Proteomics Corp. Microarrays and their manufacture
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US5942395A (en) * 1997-05-09 1999-08-24 Universite De Montreal Hybrid ribozymes and methods of use
DE19814257A1 (en) 1998-03-31 1999-10-07 Asta Medica Ag effervescent formulations
CN1322129A (en) * 1998-09-01 2001-11-14 伊迪亚股份公司 Electrically controlled transport of charged penetrants across barriers
WO2008014979A2 (en) 2006-07-31 2008-02-07 Curevac Gmbh NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
US8530436B2 (en) 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
BRPI0907087B1 (en) 2008-01-31 2021-08-17 Curevac Ag RNA MOLECULE, PHARMACEUTICAL COMPOSITION AND ITS USES IN THE TREATMENT OF DISEASES
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
SG186706A1 (en) 2010-07-30 2013-02-28 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane
AU5418290A (en) * 1989-03-31 1990-11-05 University Patents Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Journal of Controlled Release, Volume 7, issued 1988, A.K. BANGA et al., "Iontophoretic Delivery of Drugs: Fundamentals, Developments and Biomedical Applications", pages 1-24, see the entire document. *
Nature, Volume 355, issued 06 February 1992, L.C. BOCK et al., "Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin", pages 564-566, see the entire document. *
Pharmaceutical Research, Volume 9, No. 10 (Supplement), issued October 1992, R. VAN DER GEEST et al., "Iontophoresis: A Transdermal Delivery Strategy for Antisense Oligonucleotide Drugs?", page S-67, Abstract BIOTEC 2004, see entire Abstract. *
Proceedings of the National Academy of Sciences, USA, Volume 84, issued November 1987, P.L. FELGNER et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure", pages 7413-7417, see the entire document. *
The Journal of Infectious Diseases, Volume 154, No. 6, issued December 1986, L.P. GANGAROSA, Sr. et al., "Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis", pages 930-934, see the entire document. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846635B1 (en) 1999-07-30 2005-01-25 Large Scale Proteomics Corp. Microarrays and their manufacture
US6887701B2 (en) 1999-07-30 2005-05-03 Large Scale Proteomics Corporation Microarrays and their manufacture
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing

Also Published As

Publication number Publication date
JPH08510720A (en) 1996-11-12
AU6764794A (en) 1994-08-29
CA2153243A1 (en) 1994-08-18
EP0683668A4 (en) 1997-12-29
EP0683668A1 (en) 1995-11-29
WO1994017792A2 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
CA2180530A1 (en) Transdermal Device Containing Polyvinylpyrrolidone as Solubility Enhancer
PL330212A1 (en) Preparation administered by transcutaneous absorption
EP1234586A3 (en) Hepatoselective pharmaceutical actives
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
AU4261097A (en) Compositions and methods for topical application of therapeutic agents
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
WO2000038626A3 (en) Substrate composition and method of use for sequestration of skin irritants
ATE288743T1 (en) PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR ADMINISTRATION OF ACTIVE INGREDIENTS TO MUCOUS SKIN SURFACES
HUP9904023A2 (en) Use of leptin antagonists for treating insulin resistance in type ii diabetes
BG103552A (en) THERAPEUTIC MEDICINES
EP0147146A3 (en) Enhancement of transdermal drug delivery
EP0164998A3 (en) Compositions and methods of enhancing transdermal and transmembrane penetration of topical and systemic agents
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
AU7662400A (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
HUP9903348A3 (en) Transdermal therapeutic system (tts) for administering active substances for the teratment of drug dependency or drug addiction
DK0387693T3 (en) Transdermal system with incremental release of active substances and use for local or systemic cosmetic delivery of active substances
ATE208200T1 (en) TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR ADMINISTRATION OF TESTOSTERONE
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0227531A3 (en) Pyroglutamic acid esters used as dermal penetration enhancers for drugs
EP0373771A3 (en) New pharmaceutical uses for cystatins
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
WO1997017072A3 (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US US US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2153243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994915749

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 495490

Country of ref document: US

Date of ref document: 19950926

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994915749

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994915749

Country of ref document: EP